Zacks Investment Research lowered shares of Zafgen, Inc. (NASDAQ:ZFGN) from a buy rating to a hold rating in a report published on Friday morning.

According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, ValuEngine upgraded shares of Zafgen from a strong sell rating to a sell rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $6.50.

Zafgen (ZFGN) opened at 3.58 on Friday. The firm’s market capitalization is $98.39 million. The firm has a 50-day moving average of $3.48 and a 200-day moving average of $4.02. Zafgen has a 52-week low of $2.89 and a 52-week high of $5.46.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter last year, the company earned ($0.55) earnings per share. On average, equities research analysts forecast that Zafgen will post ($2.23) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/05/zafgen-inc-zfgn-downgraded-by-zacks-investment-research.html.

In other Zafgen news, insider Dennis D. Kim bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The shares were acquired at an average cost of $3.39 per share, for a total transaction of $33,900.00. Following the transaction, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 21.20% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC boosted its position in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 10,327 shares during the period. Algert Global LLC acquired a new stake in Zafgen during the 2nd quarter worth approximately $123,000. Nine Chapters Capital Management LLC acquired a new stake in Zafgen during the 1st quarter worth approximately $170,000. Wells Fargo & Company MN boosted its position in Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 40,400 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in Zafgen during the 2nd quarter worth approximately $259,000. Institutional investors and hedge funds own 48.52% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Get a free copy of the Zacks research report on Zafgen (ZFGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related stocks with our FREE daily email newsletter.